Search This Blog

Wednesday, September 22, 2021

Cassava: Top-line Interim Results from Open-label Study Evaluating Simufilam in Alzheimer’s

 

  • Cognition Scores Improved 3.2 Points on ADAS-Cog, Baseline to Month 12 (p<0.001)

  • Two Independent Biostatisticians Analyzed Changes in ADAS-Cog Scores, Baseline to Month 12

  • No Behavior Disorders on NPI in Over 50% Of Study Subjects at Month 12

  • Initiation of Pivotal Phase 3 Clinical Program Remains On-track for Q4 2021, with Special Protocol Assessments from FDA

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)